QPP Measure #PIMSH8
Oncology: Mutation testing for lung cancer completed prior to start of targeted therapy
Proportion of stage 4 NSCLC patients tested for actionable biomarkers, including EGFR, BRAF mutation; ROS1, ALK rearrangement; PD-L1 expression, and received targeted therapy or chemotherapy based on biomarker results.
Submission Methods: Registry
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com